Ananda Developments finance director Jeremy Sturgess-Smith shares promising results from preclinical studies investigating the efficacy of MRX1 in treating cardiac fibrosis and heart failure with preserved ejection fraction (HFpEF). Sturgess-Smith explained that Ananda Developments acquired MRX Medical, the company that owns the MRX1 IP, last year. The company specialises in chronic inflammatory pain conditions and cannabis-based medicinal treatments. The study shows that dosing MRX1 in mice with heart failure and preserved ejection fraction can bring heart and lung weight back to healthy levels and significantly reduce heart failure compounds. Sturgess-Smith emphasised the high unmet medical need in treating heart failure, with limited options beyond diet and exercise. Ananda Developments aims to include MRX1 as part of its treatment portfolio, alongside its existing two Phase II trials investigating Chemotherapy Induced Peripheral Neuropathy and Endometriosis. Next steps involve consultations with Dr Nadine Godsman, who led the trial, to determine whether to proceed with human studies or further mice data collection. Visit Proactive's YouTube channel for more videos, and don't forget to like, subscribe, and enable notifications for future content. #AnandaDevelopments #CardiacFibrosis #HeartFailureResearch #CannabisMedicine #MSCsMedical #ClinicalTrials #ProactiveInvestors #MedicalBreakthrough #HealthInnovation #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews